Patent & IP news for August 6, 2017

Patent Litigations

  • No new litigations this day!

USPTO Weekly Stats

8,558
published
appl'ns
7,208
granted
patents
64
ptab
decisions

Patent & IP Blogs

post image Cross-undertaking in damages - Napp Pharmaceuticals v Sandoz Limited from ipkitten.blogspot.com

What is the price of seeking an interim injunction in the Courts of England & Wales? A cross-undertaking in damages.  This is designed to compensate the respondent for any damages sustained as result of an interim ...

Share via E–mail | Twitter | Facebook

post image Sunday Surprises from ipkitten.blogspot.com

Kind reminder! The Public Consultation on the Database Directive launched by the European Commission closes on 30 August 2017. Responses to the Consultation and more details, here.
 Thrilled about upcoming events!IT for Change is ...

Share via E–mail | Twitter | Facebook

FRCP 30(b)(6) inquiries are not objectionable solely because the designation would require testimony about a corporation’s opinion or the application of law to facts from ipbiz.blogspot.com


In the post Rule 30(b)(6) at 45: Is It Still Your Friend? , some issues with 30(b)(6) depositions are addressed:


In Sigmund v. Starwood Urban Retail VI, LLC, 236 F.R.D ...

Share via E–mail | Twitter | Facebook

Judge Smith’s dissenting opinion in In re Wiechert, 370 F.2d 927 (CCPA 1967) from www.717madisonplace.com

Back in 1967, Judge Smith of the CCPA dissented from the majority in the opinion of In re Wiechert, 370 F.2d 927, 152 U.S.P.Q. 247 (C.C.P.A. 1967).  Judge ...

Share via E–mail | Twitter | Facebook

Conference <span class="amp">&amp;</span> CLE&nbsp;Calendar from www.patentdocs.org

August 8, 2017 - Patent Quality Chat webinar series (U.S. Patent and Trademark Office) - 12:00 to 1:00 pm (ET) on August 10-11, 2017 - Advanced Patent Law Seminar (Chisum Patent Academy) - Seattle, WA August ...

Share via E–mail | Twitter | Facebook

News from Abroad -- EPO Applies Doctrine of Plausibility to Small Molecule&nbsp;Pharmaceuticals from www.patentdocs.org

In Decision T 488/16, the Boards of Appeal of the European Patent Office (BoA) have revoked EP 1 169 038, which protected the blockbuster protein tyrosine kinase (PTK) inhibitor dasatinib (Sprycel®). The only request ...

Share via E–mail | Twitter | Facebook

Some content © 2007–2017 RPX Corporation.
Terms of Service & Privacy Policy
For DMCA requests contact help@priorsmart.com.